Who Exports Dexamethasone from India — 808 Suppliers Behind a $181.4M Market
India's dexamethasone export market is supplied by 808 active exporters who collectively shipped $181.4M across 8,777 shipments. DR.REDDY'S LABORATORIES LTD leads with a 22.5% market share, followed by DR REDDYS LABORATORIES LIMITED and SUN PHARMACEUTICAL INDUSTRIES LIMITED. The top 5 suppliers together control 61.6% of total export value, reflecting a concentrated market structure.
Top Dexamethasone Exporters from India — Ranked by Export Value
DR.REDDY'S LABORATORIES LTD is the leading dexamethasone exporter from India, holding a 22.5% share of the $181.4M market across 8,777 shipments from 808 exporters. The top 5 suppliers — DR.REDDY'S LABORATORIES LTD, DR REDDYS LABORATORIES LIMITED, SUN PHARMACEUTICAL INDUSTRIES LIMITED, SAKAR HEALTHCARE LIMITED, FREDUN PHARMACEUTICALS LTD — collectively control 61.6% of total export value, indicating a moderately concentrated market. Individual shares are: DR.REDDY'S LABORATORIES LTD (22.5%), DR REDDYS LABORATORIES LIMITED (16.3%), SUN PHARMACEUTICAL INDUSTRIES LIMITED (11.4%), SAKAR HEALTHCARE LIMITED (7.7%), FREDUN PHARMACEUTICALS LTD (3.7%).
Top Dexamethasone Exporters from India
Ranked by export value · 808 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | DR.REDDY'S LABORATORIES LTD CIPROFLOXACIN 0.3% AND DEXAMETHASONE 0.1 | $40.8M | 1 | 22.5% |
| 2 | DR REDDYS LABORATORIES LIMITED CIPROFLOXACIN 0.3% AND DEXAMETHASONE 0.1DEXAMETHASONE SODIUM PHOSPHATE INJECTIONDEXONA TABLETS 0.5MG 10X10 T | $29.6M | 1 | 16.3% |
| 3 | SUN PHARMACEUTICAL INDUSTRIES LIMITED CIPROFLOXACIN 0.3% AND DEXAMETHASONE 0.1CIPROFLOXACIN AND DEXAMETHASONE STERILE OTIC SUSPENSION USPDEXONA TABLETS 0.5MG 10X10 T | $20.6M | 5 | 11.4% |
| 4 | SAKAR HEALTHCARE LIMITED DEXAMETHASONE SODIUM PHOSPHATE INJECTIONDEXONA TABLETS 0.5MG 10X10 TDEXAMETHASONE SODIUM PHOSPHATE INJECTIONBP 4MG/ML | $13.9M | 6 | 7.7% |
| 5 | FREDUN PHARMACEUTICALS LTD ORJI DEXAMETHASONE B P 0 5MG TABLETPHARMACEUTICAL PRODUCTS DEXAMETHASONE TESSENTIAL PHARMACEUTICALS. DEXAMETHASONE TABLETS BP 0.5 MG. | $6.7M | 1 | 3.7% |
| 6 | MYLAN LABORATORIES LIMITED CIPROFLOXACIN 0.3% AND DEXAMETHASONE 0.1DEXAMETHASONE MYLAN INJ 8MG/2ML 5S MYL ADEXAMETHASONE VIATRIS INJ 8MG/2ML-5S-AUS | $6.1M | 4 | 3.4% |
| 7 | SENTISS PHARMA PRIVATE LIMITED DEXAMETHASONE SODIUM PHOSPHATE INJECTIONDEXAMETHASONE - AGIO SOLUTION FOR INJECTION 4MG/MLDEXAMETHASONE AGIO SOLUTION FOR INJECTIO | $5.7M | 6 | 3.1% |
| 8 | EUGIA PHARMA SPECIALITIES LIMITED CIPROFLOXACIN 0.3% AND DEXAMETHASONE 0.1 | $5.0M | 1 | 2.7% |
| 9 | DR.REDDY'S LABORATORIES LIMITED CIPROFLOXACIN 0.3% AND DEXAMETHASONE 0.1 | $4.2M | 1 | 2.3% |
| 10 | SOMERSET THERAPEUTICS LIMITED CIPROFLOXACIN 0.3% AND DEXAMETHASONE 0.1 | $3.0M | 1 | 1.7% |
| 11 | SUN PHARMACEUTICAL INDUSTRIES LTD CIPROFLOXACIN 0.3% AND DEXAMETHASONE 0.1CIPROFLOXACIN AND DEXAMETHASONE STERILE OTIC SUSPENSION USPDEXONA TABLETS 0.5MG 10X10 T | $2.8M | 3 | 1.5% |
| 12 | ZYDUS LIFESCIENCES LIMITED CIPROFLOXACIN 0.3% AND DEXAMETHASONE 0.1DEXONA TABLETS 0.5MG 10X10 TDEXONA E/E DROP 5ML | $2.6M | 6 | 1.4% |
| 13 | AGIO PHARMACEUTICALS LIMITED DEXAMETHASONE - AGIO SOLUTION FOR INJECTION 4MG/MLDEXAMETHASONE SODIUM PHOSPHATE INJECTIONDEXAMETHASONE AGIO SOLUTION FOR INJECTIO | $1.9M | 7 | 1.1% |
| 14 | SOMERSET THERAPEUTICS PRIVATE LIMITED CIPROFLOXACIN 0.3% AND DEXAMETHASONE 0.1 | $1.5M | 1 | 0.8% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Dexamethasone exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Dr. Reddy's Laboratories Ltd. | Approved | Yes | Yes | Multiple | Dr. Reddy's has FDA approvals, WHO-GMP, and EU GMP certifications. |
| Sun Pharmaceutical Industries Limited | Approved | Yes | Yes | Multiple | Sun Pharma holds FDA approvals, WHO-GMP, and EU GMP certifications. |
| Zydus Lifesciences Limited | Approved | Yes | Yes | Multiple | Zydus has FDA approvals, WHO-GMP, and EU GMP certifications. |
| Mylan Laboratories Limited | Approved | Yes | Yes | Multiple | Mylan holds FDA approvals, WHO-GMP, and EU GMP certifications. |
| Sakar Healthcare Limited | Not Listed | Yes | Yes | Not Applicable | Sakar Healthcare has WHO-GMP and EU GMP certifications. |
| Fredun Pharmaceuticals Ltd. | Not Listed | Yes | Yes | Not Applicable | Fredun Pharmaceuticals holds WHO-GMP and EU GMP certifications. |
| Sentiss Pharma Private Limited | Not Listed | Yes | Yes | Not Applicable | Sentiss Pharma has WHO-GMP and EU GMP certifications. |
| Eugia Pharma Specialities Limited | Approved | Yes | Yes | Multiple | Eugia Pharma holds FDA approvals, WHO-GMP, and EU GMP certifications. |
| Somerset Therapeutics Limited | Approved | Yes | Yes | Multiple | Somerset Therapeutics has FDA approvals, WHO-GMP, and EU GMP certifications. |
TransData Nexus reviewed the regulatory standing of 9 leading Dexamethasone exporters from India. 6 hold US FDA facility approvals, 9 maintain WHO-GMP certification, and 9 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Dexamethasone sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as "India's pharmaceutical capital," has been a pivotal center for bulk drug manufacturing since the establishment of Indian Drugs and Pharmaceuticals Limited (IDPL) in 1961. The city contributes significantly to India's pharmaceutical output, producing one-third of the nation's bulk drugs and 16% of biotechnology products as of 2010. This robust infrastructure supports the production of Active Pharmaceutical Ingredients (APIs) like Dexamethasone, ensuring a steady supply for both domestic formulations and international exports.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its dominance in pharmaceutical formulations. Gujarat holds a 33% share in drug manufacturing and a 28% share in drug exports, with Ahmedabad and Vadodara being central to this achievement. The region hosts numerous USFDA-certified facilities, enabling the production of high-quality Dexamethasone formulations that meet stringent international standards. Companies like Alembic Pharmaceuticals, headquartered in Vadodara, exemplify the area's capacity for producing and exporting pharmaceutical products globally.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for India's pharmaceutical industry. Mumbai's strategic coastal location and well-developed port facilities facilitate the efficient export of pharmaceutical products, including Dexamethasone, to international markets. The region's proximity to major shipping routes and its established logistics infrastructure make it an ideal hub for pharmaceutical exports, ensuring timely delivery and compliance with global regulatory requirements.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing zone, primarily due to favorable tax incentives and supportive government policies. This area attracts numerous pharmaceutical companies seeking cost-effective production solutions. While traditionally focused on domestic supply, the region's growing capabilities in producing formulations like Dexamethasone position it as a potential player in the export market.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different clusters to mitigate risks associated with regional disruptions and ensure a consistent supply of Dexamethasone.
- Evaluate Supplier Credentials: Prioritize partnerships with manufacturers holding USFDA certifications and a proven track record in producing high-quality Dexamethasone formulations.
- Leverage Export Hubs: Utilize the logistical advantages of the Mumbai-Thane-Raigad region to streamline export processes and reduce lead times for international shipments.
- Monitor Regulatory Compliance: Stay informed about regulatory changes in key export destinations, particularly the United States, which accounts for 62.7% of Dexamethasone exports, to ensure uninterrupted market access.
By strategically sourcing from India's diverse pharmaceutical clusters and adhering to these recommendations, TransData Nexus can optimize its supply chain for Dexamethasone, ensuring reliability, quality, and compliance in its operations.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Dexamethasone exporters from India
Dr. Reddy's Laboratories Ltd. — Dr. Reddy's acquires Mayne Pharma's U.S. generic portfolio
Dr. Reddy's Laboratories announced an agreement to acquire Mayne Pharma's U.S. generic prescription product portfolio, including 45 commercial products and 4 pipeline products. - IMPACT: This acquisition is expected to enhance Dr. Reddy's U.S. market presence, potentially increasing Dexamethasone exports.
Impact: This acquisition is expected to enhance Dr. Reddy's U.S. market presence, potentially increasing Dexamethasone exports.
Dr. Reddy's Laboratories Ltd. — Dr. Reddy's sells 14 ANDAs to Senores Pharmaceuticals
Dr. Reddy's Laboratories entered into agreements to sell 14 Abbreviated New Drug Applications (ANDAs) to Senores Pharmaceuticals, comprising 13 approved and 1 pending approval from the USFDA. - IMPACT: This divestiture may allow Dr. Reddy's to reallocate resources, potentially affecting Dexamethasone export strategies.
Impact: This divestiture may allow Dr. Reddy's to reallocate resources, potentially affecting Dexamethasone export strategies.
Dr. Reddy's Laboratories Ltd. — Dr. Reddy's recalls drugs in U.S. market
Dr. Reddy's Laboratories initiated a recall of Eszopiclone tablets and Allopurinol tablets in the U.S. due to manufacturing issues, including failed impurities and presence of foreign substances. - IMPACT: Such recalls could impact the company's reputation and may indirectly affect Dexamethasone exports.
Impact: Such recalls could impact the company's reputation and may indirectly affect Dexamethasone exports.
Common Questions — Dexamethasone Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which dexamethasone supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, DR.REDDY'S LABORATORIES LTD leads with 46 recorded shipments worth $40.8M. DR REDDYS LABORATORIES LIMITED (22 shipments) and SUN PHARMACEUTICAL INDUSTRIES LIMITED (65 shipments) are also established high-volume exporters.
Q How many dexamethasone manufacturers are there in India?
India has 808 active dexamethasone exporters with a combined export market of $181.4M across 8,777 shipments to 176 countries. The top 5 suppliers hold 61.6% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for dexamethasone from India?
Average FOB unit price: $26.04 per unit, ranging from $0.00 to $23333.33. Average shipment value: $20.7K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 808 verified Indian exporters of Dexamethasone ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 8,777 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 176 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
8,777 Verified Shipments
808 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists